Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2015 - At today's Annual General Meeting (AGM) of Actelion Ltd (SIX: ATLN), held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a significant majority. The meeting was attended by 249 shareholders. A total of 66'512'248 shares, or 58.28% of the total outstanding shares, was represented. Led by the Chairman of the Board, Jean-Pierre Garnier, the company presented a review of the 2014 performance. Highlights included the outstanding financial results, the highly successful launch of Opsumit®, the sustained demand for key products such as Tracleer® and Veletri®, the excellent Phase...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>